I-NDMA ihlelwa njengomhlaza womntu onokwenzeka. Oku kuthetha ukuba ukuvezwa kwexesha elide kwinqanaba elingaphezulu koko kubonwa njengekhuselekile kunokunyusa umngcipheko womhlaza. I-Health Canada icebisa ukuba akukho mngcipheko okhawulezayo wokuqhubeka nokuthatha i-APO-Amitriptyline okanye i-Elavil (amitriptyline) ekhunjulwayo ekubeni umngcipheko womhlaza unobungozi bexesha elide (yonke imihla kwiminyaka eyi-70) kwi-NDMA edlula amanqanaba akhuselekileyo.
I-Health Canada igcina uluhlu lwamachiza akhunjulwayo e-amitriptyline achatshazelwa ngulo mba. Nceda ubone ingcebiso epheleleyo ngolwazi oluthe kratya, kubandakanywa ngakumbi malunga nomngcipheko kunye nokuba yintoni izigulane kufuneka ziyenze.
| inkampani | imveliso | amandla | DIN | uLote | Ukuphelelwa |
| Inkampani AA Pharma Inc. | Elavil
(Amitriptyline Hydrochloride Iitafile ze-USP) |
10 mg | 00335053 | I-PY1829 | 12/2023 |
| Inkampani AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Iitafile ze-USP) |
10 mg | 00335053 | I-PY1830 | 12/2023 |
| I-Apotex Inc. | APO-Amitriptyline
(Amitriptyline Hydrochloride Iitafile ze-USP) |
10 mg | 02403137 | I-PY1832 | 12/2023 |
INTO ONOKUYITHATHA KWELI NQAKU:
- Health Canada is advising that there is no immediate risk in continuing to take the recalled APO-Amitriptyline or Elavil (amitriptyline) since the potential risk of cancer is with long-term exposure (every day for 70 years) to NDMA that exceeds safe levels.
- .
- .
